TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Nordic Drugs AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
363,312
|
337,525
|
300,076 |
| Financial expenses |
1,436
|
14
|
75 |
| Earnings before taxes |
37,922
|
14,904
|
-2,971 |
| EBITDA |
38,165
|
14,100
|
-3,923 |
| Total assets |
186,163
|
170,179
|
139,098 |
| Current assets |
185,634
|
169,078
|
136,687 |
| Current liabilities |
55,450
|
67,440
|
45,916 |
| Equity capital |
127,430
|
97,900
|
88,366 |
| - share capital |
20,000
|
20,000
|
20,000 |
| Employees (average) |
25
|
25
|
26 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
68.5%
|
57.5%
|
63.5% |
| Turnover per employee |
14,532
|
13,501
|
11,541 |
| Profit as a percentage of turnover |
10.4%
|
4.4%
|
-1.0% |
| Return on assets (ROA) |
21.1%
|
8.8%
|
-2.1% |
| Current ratio |
334.8%
|
250.7%
|
297.7% |
| Return on equity (ROE) |
29.8%
|
15.2%
|
-3.4% |
| Change turnover |
25,787
|
37,449
|
60,035 |
| Change turnover % |
8%
|
12%
|
25% |
| Chg. No. of employees |
0
|
-1
|
0 |
| Chg. No. of employees % |
0%
|
-4%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.